<DOC>
	<DOCNO>NCT01771653</DOCNO>
	<brief_summary>The purpose observational study compare two approve treatment regimen ( ) contain boceprevir telaprevir , part standard care treatment hepatitis C .</brief_summary>
	<brief_title>Comparison Two Triple Regimens Treatment Retreatment Chronic Hepatitis C Infection</brief_title>
	<detailed_description>The objective study compare effect add 2 oral hepatitis C virus ( HCV ) protease inhibitor , telaprevir versus boceprevir , part current standard treatment regimen ( pegylated-interferon-alpha + ribavirin ) HCV Genotype-1 infection . Data obtain medical record consent patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Age 1864 year HCV genotype 1 HCV RNA &gt; 100,000 Liver biopsy within 5 year enrollment Absolute neutrophil count least 1200 per cubic millimeter Platelet count least 90,000 per cubic millimeter Hemoglobin level least 12 g per deciliter Signed informed consent Health Insurance Portability Accountability Act ( HIPAA ) form HCV genotype genotype 1 Immunocompromised condition include HIV , transplant immunosuppressive drug Decompensated liver disease hepatocellular carcinoma Any type active cancer Active autoimmune disorder Major psychiatric disorder Active drug alcohol use Pregnancy lactation Patients allergy drug use study Drugs may interact boceprevir telaprevir list package insert</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Hepatitis C infection</keyword>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>HCV</keyword>
</DOC>